Smith & Nephew to go before FDA panel
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic & Rehabilitation Devices Panel will review the firm's PMA application for its Birmingham Hip Resurfacing product Sept. 8 in Gaithersburg, Md. The cemented femoral component and uncemented acetabular component preserve the femoral head, unlike conventional hip surgery. Product is tailored to younger, more active patients, according to the firm (1"The Gray Sheet" March 15, 2004, p. 22). The panel will meet on Sept. 9 to discuss clinical trial designs for spinal devices for treating mild-to-moderate low back pain...
You may also be interested in...
New Hip Replacement Reflects Well On Smith & Nephew Sales Team – CEO
Smith & Nephew says the launch of its Reflection hip replacement implant in January has given its sales personnel increased standing with doctors to market the firm's full suite of hip products
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.